• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[促红细胞生成素在改善伤口愈合中的作用]

[The role of erythropoietin in improvement of wound healing].

作者信息

Sorg H, Kuhbier J W, Menger B, Reimers K, Harder Y, Vogt P M

机构信息

Klinik für Plastische, Hand- und Wiederherstellungschirurgie, Medizinische Hochschule Hannover, Deutschland.

出版信息

Chirurg. 2010 Nov;81(11):993-8. doi: 10.1007/s00104-010-1978-3.

DOI:10.1007/s00104-010-1978-3
PMID:20835693
Abstract

Pleiotropic substances are characterized by their versatile and complex range of actions which makes them potential new active agents for the therapy of wounds. Besides its known effect to increase red blood cell production, the glycoprotein hormone erythropoietin (EPO) has been found to demonstrate a tissue protective effect in several other organs. The administration of EPO during skin wound healing is most likely essentially based on its cytopotective, proangiogenic, antiapoptotic and antiinflammatory effects. Herein EPO stimulates a coordinated interaction of different types of cells at a low or only a single dose. This review article aims to present the advantages and disadvantages of EPO administration in different experimental models to study the healing and regeneration processes of the skin and discusses possible clinical applications.

摘要

多效性物质的特点是其作用广泛且复杂,这使其成为伤口治疗潜在的新型活性剂。除了已知的增加红细胞生成的作用外,糖蛋白激素促红细胞生成素(EPO)已被发现在其他几个器官中具有组织保护作用。在皮肤伤口愈合过程中给予EPO很可能主要基于其细胞保护、促血管生成、抗凋亡和抗炎作用。在此,EPO以低剂量或仅单一剂量就能刺激不同类型细胞的协同相互作用。这篇综述文章旨在阐述在不同实验模型中给予EPO以研究皮肤愈合和再生过程的优缺点,并讨论其可能的临床应用。

相似文献

1
[The role of erythropoietin in improvement of wound healing].[促红细胞生成素在改善伤口愈合中的作用]
Chirurg. 2010 Nov;81(11):993-8. doi: 10.1007/s00104-010-1978-3.
2
Skin regeneration with conical and hair follicle structure of deep second-degree scalding injuries via combined expression of the EPO receptor and beta common receptor by local subcutaneous injection of nanosized rhEPO.通过局部皮下注射纳米 rhEPO 联合表达 EPO 受体和β共同受体促进深二度烫伤创面的圆锥形和毛囊结构皮肤再生。
Int J Nanomedicine. 2012;7:1227-37. doi: 10.2147/IJN.S28186. Epub 2012 Mar 6.
3
A novel role for erythropoietin during fibrin-induced wound-healing response.促红细胞生成素在纤维蛋白诱导的伤口愈合反应中的新作用。
Am J Pathol. 2003 Sep;163(3):993-1000. doi: 10.1016/S0002-9440(10)63459-1.
4
The nonhematopoietic effects of erythropoietin in skin regeneration and repair: from basic research to clinical use.促红细胞生成素在皮肤再生和修复中的非造血作用:从基础研究到临床应用。
Med Res Rev. 2013 May;33(3):637-64. doi: 10.1002/med.21259. Epub 2012 Mar 19.
5
Effects of erythropoietin in skin wound healing are dose related.促红细胞生成素在皮肤伤口愈合中的作用与剂量相关。
FASEB J. 2009 Sep;23(9):3049-58. doi: 10.1096/fj.08-109991. Epub 2009 Apr 27.
6
Erythropoietin improves functional and histological recovery of traumatized skeletal muscle tissue.促红细胞生成素可改善创伤骨骼肌组织的功能和组织学恢复。
J Orthop Res. 2008 Dec;26(12):1618-26. doi: 10.1002/jor.20692.
7
Topical erythropoietin promotes wound repair in diabetic rats.局部应用促红细胞生成素促进糖尿病大鼠创面修复。
J Invest Dermatol. 2010 Jan;130(1):287-94. doi: 10.1038/jid.2009.219.
8
Erythropoietin, a novel repurposed drug: an innovative treatment for wound healing in patients with diabetes mellitus.促红细胞生成素,一种新型的再利用药物:用于治疗糖尿病患者伤口愈合的创新疗法。
Wound Repair Regen. 2014 Jan-Feb;22(1):23-33. doi: 10.1111/wrr.12135. Epub 2013 Dec 13.
9
Erythropoietin stimulates wound healing and angiogenesis in mice.促红细胞生成素可刺激小鼠伤口愈合和血管生成。
J Invest Surg. 2006 May-Jun;19(3):163-73. doi: 10.1080/08941930600674694.
10
Multiple doses of erythropoietin impair liver regeneration by increasing TNF-alpha, the Bax to Bcl-xL ratio and apoptotic cell death.多剂量促红细胞生成素通过增加肿瘤坏死因子-α、Bax与Bcl-xL的比值以及凋亡性细胞死亡来损害肝脏再生。
PLoS One. 2008;3(12):e3924. doi: 10.1371/journal.pone.0003924. Epub 2008 Dec 11.

本文引用的文献

1
Down with the erythropoietin. Long live the erythropoietin!打倒促红细胞生成素!万岁促红细胞生成素!
Curr Drug Targets. 2009 Oct;10(10):1028-32. doi: 10.2174/138945009789577981.
2
Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing.非促红细胞生成组织保护化合物是伤口愈合的高效促进剂。
Mol Med. 2009 Jul-Aug;15(7-8):235-41. doi: 10.2119/molmed.2009.00051. Epub 2009 Apr 16.
3
Modulation of circulating cell-endothelial cell interaction by erythropoietin in lean and obese mice with cecal ligation and puncture.
促红细胞生成素对盲肠结扎穿刺致瘦小鼠和肥胖小鼠循环细胞与内皮细胞相互作用的调节作用
Pathophysiology. 2010 Feb;17(1):9-18. doi: 10.1016/j.pathophys.2009.04.002. Epub 2009 Jun 5.
4
Interferon-alfa- and erythropoetin-associated cerebral vasoconstriction.干扰素α和促红细胞生成素相关的脑血管收缩。
Cephalalgia. 2009 Dec;29(12):1340-3. doi: 10.1111/j.1468-2982.2009.01875.x. Epub 2009 Jun 1.
5
Effects of erythropoietin in skin wound healing are dose related.促红细胞生成素在皮肤伤口愈合中的作用与剂量相关。
FASEB J. 2009 Sep;23(9):3049-58. doi: 10.1096/fj.08-109991. Epub 2009 Apr 27.
6
Risk factors for leukemic transformation in patients with primary myelofibrosis.原发性骨髓纤维化患者白血病转化的危险因素。
Cancer. 2008 Jun 15;112(12):2726-32. doi: 10.1002/cncr.23505.
7
Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.促红细胞生成素在慢性肾脏病贫血患者中的应用:克服现有疗法的药理学和药物经济学局限性
Mayo Clin Proc. 2007 Nov;82(11):1371-80. doi: 10.4065/82.11.1371.
8
Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin.人毛囊是促红细胞生成素的肾外来源和非造血靶点。
FASEB J. 2007 Oct;21(12):3346-54. doi: 10.1096/fj.07-8628com. Epub 2007 May 31.
9
Attenuation of inflammation and apoptosis by pre- and posttreatment of darbepoetin-alpha in acute liver failure of mice.达贝泊汀-α 预处理和后处理对小鼠急性肝衰竭炎症和细胞凋亡的减轻作用。
Am J Pathol. 2007 Jun;170(6):1954-63. doi: 10.2353/ajpath.2007.061056.
10
Treatment of severe scleroderma skin ulcers with recombinant human erythropoietin.用重组人促红细胞生成素治疗重度硬皮病皮肤溃疡。
Clin Exp Dermatol. 2007 May;32(3):287-90. doi: 10.1111/j.1365-2230.2007.02363.x.